

OCT 5 1999

K993111

SUMMARY OF SAFETY AND EFFECTIVENESS

Sponsor: Biomet, Inc.
Airport Industrial Park
P.O. Box 587
Warsaw, IN 46581-0587

Contact Person: Dalene Hufziger Binkley
(219) 372-1612

Trade Name: Ascent Knee System

Classification Name: Knee joint patello-femorotibial polymer/metal/polymer semi-constrained cemented prosthesis (CFR 888.3560).

Device Description: The Ascent Closed Box Posterior Stabilized Femoral Component is a stemmable knee component designed for use in cases where extensive ligament damage has occurred. This design is based upon the features of the currently marketed Performance Closed Box Knee Components with certain modifications.

There are five sizes available in both right and left configurations. The femoral articulation is the same as the Performance Posterior Stabilized Knee (K936274). The anatomic component design allows the surgeon to reconstruct the anatomic dimensions and kinematics of the natural femur. The femoral component has an Interlok finish for use in cemented applications.

The Ascent Closed Box PS Femoral Component can be used with either a constrained or PS tibial bearing. The femoral component also has independent posterior and distal augments to correct bone loss deficiencies and can still be used with previously cleared Performance stems and locking screw.

Potential Risks: The potential risks associated with this device are the same as with any joint replacement disease. These include, but not limited to:

Reaction to bone cement	Blood vessel damage	Bone fracture
Deformity of the joint	Soft tissue imbalance	Infection
Cardiovascular diseases	Delayed wound healing	Hematoma
Fracture of the cement	Metal sensitivity	Dislocation
Implant loosening/Migration	Fracture of the components	Excessive wear
Tissue growth failure	Nerve damage	

000061



OCT 5 1999

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Ms. Mary L. Verstynen
Manager of Clinical Affairs
Biomet, Inc.
P.O. Box 587
Warsaw, Indiana 46581-0587

Re: K993111
Trade Name: Ascent Knee System
Regulatory Class: II
Product Code: JWH
Dated: September 16, 1999
Received: September 17, 1999

Dear Ms. Verstynen:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

Page 2 – Ms. Mary L. Verstynen

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or at (301) 443-6597, or at its Internet address "<http://www.fda.gov/cdrh/dsmamain.html>".

Sincerely yours,



fm
Celia M. Witten, Ph.D., M.D.
Director
Division of General and
Restorative Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

